NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara Print E-mail
By Staff and Wire Reports   
Friday, 03 January 2014 18:00
Below is a look at some of the headlines for companies that made news in the healthcare sector on January 3, 2014

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP)
, a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, announced the European Commission has granted orphan drug designation to Natpara® (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism. Natpara is a bioengineered replacement for endogenous parathyroid hormone (PTH) that NPS has developed for the treatment of hypoparathyroidism, a rare endocrine disorder in which the body produces insufficient levels of parathyroid hormone, a principal regulatory of the body's mineral homeostasis. Orphan drug designation in the European Union (EU) is given to products that are designed for the diagnosis, prevention or treatment of rare diseases that are life-threatening or chronically debilitating. A disease is defined as rare in the EU if it affects no more than five in 10,000 people.

“We are very pleased that Natpara has received orphan drug status in the EU,” said Francois Nader, MD, president and chief executive officer of NPS Pharmaceuticals. “As a global rare disease biopharmaceutical company, this aligns with our commitment to deliver innovative therapies that transform the lives of patients around the world. Hypoparathyroidism patients face a significant burden of disease given the multitude of physical, cognitive, and emotional symptoms associated with this disorder. Natpara could be the first PTH replacement therapy to treat this condition.”

The company was also granted orphan drug status by the U.S. Food and Drug Administration (FDA) in 2007. The company submitted its U.S. Biologic License Application to FDA in October 2013.



Also Friday:



Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
today announced the appointment of Richard Sachse, MD, PhD, as Senior Vice President, Chief Scientific Officer. Before joining Aeterna Zentaris, Dr. Sachse was Vice President, Head of Global Translational Medicine at Boehringer Ingelheim.

Analogic Corporation (Nasdaq:ALOG)
, enabling the world's medical imaging and aviation security technology, today announced that Jim Green, president and CEO, will be presenting at two investor conferences in January 2014.

Cellular Biomedicine Group Inc. (OTCQB:CBMG)
, a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the appointment of Bizuo (Tony) Liu as Chief Financial Officer and Board Secretary and the election of Nadir Patel as Independent Director, Chairman of the Audit Committee of the board of directors of CBMG.

The Affordable Care Act has the potential to insure millions of Americans, but can it predict the outcome of the professional football playoffs? This is the question a handful of people at eHealth (NASDAQ: EHTH) asked themselves after reviewing the results of a new email survey of 1,290 adults who bought their health insurance through eHealthInsurance.com, the nation's first and largest private health insurance exchange for individuals, families and small businesses.

Express Scripts Holding Company (Nasdaq: ESRX)
announced that it will present at the J.P. Morgan Healthcare Conference on January 15, 2014 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) at the Westin St. Francis in San Francisco, CA.  

Helen of Troy Limited (NASDAQ, NM:HELE)
designer, developer and worldwide marketer of brand-name houseware, healthcare/home environment and personal care consumer products, today announced that it will conduct a conference call to discuss its third quarter fiscal 2014 results on Thursday, January 9, 2014 at 4:45 p.m. Eastern Time.

HearAtLast Holdings Inc. (OTC Pink: HRAL)
is pleased to announce that it has developed a proprietary software program that is used to screen for hearing loss.

Insulet Corporation (NASDAQ: PODD)
, the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced the Company will participate in the 32nd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco.

Masimo (NASDAQ: MASI)
today announced that its management is scheduled to present at the 32nd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 15, 2014, at 2:00 p.m. Pacific Time.

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP)
, a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Commission has granted orphan drug designation to Natpara® (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism.

RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX)
announced that it has received Orphan Drug designation from U.S. FDA’s Office of Orphan Products Development (OOPD) for its drug candidate, Thymosin beta 4 (Tβ4), for the treatment of Neurotrophic Keratopathy (NK), a serious degenerative disease of the corneal epithelium (the outside layer of the eye).

Rite Aid Corporation (NYSE:RAD)
today announced sales results for December.

Tauriga Sciences, Inc. (OTCQB:TAUG)
, a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, has today announced that it has a received a comprehensive update from Immunovative Therapies Ltd. ("ITL") highlighting some potentially positive developments.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)
announced today the launch of the Authorized Generic of Detrol®* LA (tolterodine tartrate extended-release capsules) 2 mg and 4 mg in the U.S. market. Detrol® LA had annual sales of approximately $571.5 million in the U.S., according to IMS data as of September 30, 2013.

VG Life Sciences, Inc., (OTC Pink: VGLS)
a biotechnology company. Pursuant to a vote of the holders having a majority of the votes of the Company on December 31, 2013, the number of authorized shares of Common Stock of the Company has been increased to 150,000,000.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter